Details of the Drug
General Information of Drug (ID: DMLK4WO)
Drug Name |
8R-Lisuride
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
BKRGVLQUQGGVSM-RDTXWAMCSA-N; S-(-)-Lisuride; 8R-lisuride; NCGC00163158-01; Biomol-NT_000024; Lopac0_000781; BPBio1_001092; CHEMBL1528238; CHEBI:93550; BDBM22867; CCG-204866; L-122; EU-0100781; SR-01000075971; SR-01000075971-1; BRD-K88871508-001-01-9; 1,1-diethyl-3-(9,10-didehydro-6-methyl-8beta-ergolinyl)urea; N'-(9,10-Didehydro-6-methylergoline-8beta-yl)-N,N-diethylurea; 1,1-diethyl-3-[(8beta)-6-methyl-9,10-didehydroergolin-8-yl]urea; S(-)-N'-[(8a)-9,10-Didehydro-6-methylergolin-8-yl]-N,N-diethyl-urea
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 338.4 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.7 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||